Therapeutic Frontiers Ltd

Exacerbations of asthma and COPD, primarily triggered by respiratory viral infections, are the major cause of both the morbidity and mortality associated with the diseases, representing a significant unmet medical need. Traditionally, new medical entities (NMEs) for exacerbations enlist large scale, multi-centre studies, over prolonged durations with vast accompanying costs to the pharmaceutical industry, hampering innovation and clinical progress. Therapeutic Frontiers (TF) offers a radical alternative approach to clinical trials in asthma and COPD exacerbations and respiratory infection, providing the human rhinovirus experimental-infection model for the study of NMEs. Advantages of our approach include: • Controlled dose, delivery and time points for all study volunteers, alleviating variables associated with community acquired infection. • In-depth understanding of the infection cycle delivering robust data on a broad range of clinically relevant endpoints. • Application of state-of-the-art techniques provides important disease processes understanding along with valuable mode-of-action insight of novel therapeutic interventions. The result is a uniquely tailored investigation package, providing information and insight into your NME like never before.